Lemtrada savings card: as little as $0 a treatment with commercial insurance

Lemtrada is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Lemtrada is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameLemtrada

Authorized genericalemtuzumab

Regular genericalemtuzumab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Lemtrada?

The original

–

Brand nameThe maker’s card

LEMTRADA Co-Pay Program

Savings card from Sanofi

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a treatment

Or call 1-855-676-6326.

In the maker’s words

“With the Lemtrada Copay Program, eligible, commercially insured patients may pay as little as $0 for treatment.”

From the maker’s offer on lemtrada.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Lemtrada itself, from the same company, sold without the brand name, and usually for less. For now Lemtrada is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Lemtrada is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Relapsing multiple sclerosis (MS)

What the FDA label says

LEMTRADA is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

Source: the FDA label for Lemtrada (Genzyme Corporation), November 3, 2025. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/lemtrada/